vincenzo Cerullo
vincenzo Cerullo
Professor Biological Drugs, University of Helsinki
Verified email at helsinki.fi - Homepage
Title
Cited by
Cited by
Year
Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF
A Koski, L Kangasniemi, S Escutenaire, S Pesonen, V Cerullo, I Diaconu, ...
Molecular Therapy 18 (10), 1874-1884, 2010
2082010
Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients
V Cerullo, S Pesonen, I Diaconu, S Escutenaire, PT Arstila, M Ugolini, ...
Cancer research 70 (11), 4297-4309, 2010
2042010
Ischemic Neoangiogenesis Enhanced by β2-Adrenergic Receptor Overexpression: A Novel Role for the Endothelial Adrenergic System
G Iaccarino, M Ciccarelli, D Sorriento, G Galasso, A Campanile, G Santulli, ...
Circulation research 97 (11), 1182-1189, 2005
1852005
Armed oncolytic virus enhances immune functions of chimeric antigen receptor–modified T cells in solid tumors
N Nishio, I Diaconu, H Liu, V Cerullo, I Caruana, V Hoyos, ...
Cancer research 74 (18), 5195-5205, 2014
1692014
Toll-like receptor 9 triggers an innate immune response to helper-dependent adenoviral vectors
V Cerullo, MP Seiler, V Mane, N Brunetti-Pierri, C Clarke, TK Bertin, ...
Molecular Therapy 15 (2), 378-385, 2007
1572007
Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus
I Diaconu, V Cerullo, MLM Hirvinen, S Escutenaire, M Ugolini, ...
Cancer research 72 (9), 2327-2338, 2012
1492012
Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus
V Cerullo, I Diaconu, L Kangasniemi, M Rajecki, S Escutenaire, A Koski, ...
Molecular Therapy 19 (9), 1737-1746, 2011
1432011
PEGylated helper-dependent adenoviral vectors: highly efficient vectors with an enhanced safety profile
MA Croyle, HT Le, KD Linse, V Cerullo, G Toietta, A Beaudet, L Pastore
Gene therapy 12 (7), 579-587, 2005
1352005
Antiviral and antitumor T-cell immunity in patients treated with GM-CSF–coding oncolytic adenovirus
A Kanerva, P Nokisalmi, I Diaconu, A Koski, V Cerullo, I Liikanen, ...
Clinical Cancer Research 19 (10), 2734-2744, 2013
1272013
Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients
I Liikanen, L Ahtiainen, MLM Hirvinen, S Bramante, V Cerullo, ...
Molecular Therapy 21 (6), 1212-1223, 2013
1242013
Oncolytic immunotherapy of advanced solid tumors with a CD40L-expressing replicating adenovirus: assessment of safety and immunologic responses in patients
S Pesonen, I Diaconu, L Kangasniemi, T Ranki, A Kanerva, SK Pesonen, ...
Cancer research 72 (7), 1621-1631, 2012
1242012
Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4
JD Dias, O Hemminki, I Diaconu, M Hirvinen, A Bonetti, K Guse, ...
Gene therapy 19 (10), 988-998, 2012
1092012
Suppression of neuropil aggregates and neurological symptoms by an intracellular antibody implicates the cytoplasmic toxicity of mutant huntingtin
CE Wang, H Zhou, JR McGuire, V Cerullo, B Lee, SH Li, XJ Li
The Journal of cell biology 181 (5), 803-816, 2008
1052008
Oncolytic adenovirus ICOVIR-7 in patients with advanced and refractory solid tumors
P Nokisalmi, S Pesonen, S Escutenaire, M Särkioja, M Raki, V Cerullo, ...
Clinical Cancer Research 16 (11), 3035-3043, 2010
1022010
Integrin targeted oncolytic adenoviruses Ad5‐D24‐RGD and Ad5‐RGD‐D24‐GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors
S Pesonen, I Diaconu, V Cerullo, S Escutenaire, M Raki, L Kangasniemi, ...
International journal of cancer 130 (8), 1937-1947, 2012
1002012
Oncolytic vaccinia virus for the treatment of cancer
K Guse, V Cerullo, A Hemminki
Expert opinion on biological therapy 11 (5), 595-608, 2011
892011
AKT participates in endothelial dysfunction in hypertension
G Iaccarino, M Ciccarelli, D Sorriento, E Cipolletta, V Cerullo, GL Iovino, ...
Circulation 109 (21), 2587-2593, 2004
852004
An oncolytic adenovirus enhanced for toll-like receptor 9 stimulation increases antitumor immune responses and tumor clearance
V Cerullo, I Diaconu, V Romano, M Hirvinen, M Ugolini, S Escutenaire, ...
Molecular Therapy 20 (11), 2076-2086, 2012
812012
Prolonged systemic circulation of chimeric oncolytic adenovirus Ad5/3-Cox2L-D24 in patients with metastatic and refractory solid tumors
S Pesonen, P Nokisalmi, S Escutenaire, M Särkioja, M Raki, V Cerullo, ...
Gene therapy 17 (7), 892-904, 2010
802010
Immune response to helper dependent adenoviral mediated liver gene therapy: challenges and prospects
MP Seiler, V Cerullo, B Lee
Current gene therapy 7 (5), 297-305, 2007
752007
The system can't perform the operation now. Try again later.
Articles 1–20